Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Nat Med. 2015 Jun 24;21(8):906–913. doi: 10.1038/nm.3908

Figure 1.

Figure 1

AIM2 is distinct from ASC during colitis-associated colon cancer. (a) Induction procedure for the AOM/DSS model of CAC. (b–d) Weight loss (b), % survival (d, days) (c) and average clinical scores (d) in Aim2−/− (n = 25), Asc−/− (n = 11) and wild-type (n = 30) mice following induction of CAC using AOM/DSS. Mock wild-type animals (n = 10) received a single i.p. injection of AOM and were given regular drinking water instead of DSS. Error bars, s.e.m. (e) H&E staining of colons from AOM/DSS-treated wild-type, Aim2−/− and Asc−/− mice and (f) semiquantitative scoring of inflammation in colons from AOM/DSS-treated wild-type and Aim2−/− mice (n = 6 for WT AOM/Mock and Aim2−/− AOM/DSS, and n = 5 for WT AOM/DSS and Aim2−/− AOM/Mock). Images were taken at 200× magnification; scale bars, 100 µm. (g) Inflammatory cytokine mRNA (AU, arbitrary units) (n = 3 for WT AOM/Mock and Aim2−/− AOM/Mock, and n = 6 for WT AOM/DSS and Aim2−/− AOM/DSS) and (h) protein expression in wild-type and Aim2−/− colons (n = 5 for WT AOM/Mock and Aim2−/− AOM/Mock, n = 10 for WT AOM/DSS and n = 8 for Aim2−/− AOM/DSS). (i) Caspase-1 activation in wild-type and Aim2−/− colons and (j) IL-1β and IL-18 production in wild-type, Aim2−/− and Asc−/− colons (n = 5 for WT AOM/Mock, Aim2−/− AOM/Mock and Asc−/− AOM/Mock, and n = 10 for WT AOM/DSS, n = 8 for Aim2−/− AOM/DSS and n = 5 for Asc−/− AOM/DSS). Error bars, s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001; b,d,j, one-way ANOVA (Tukey's multiple-comparisons test); c, log-rank test.